Brian Vastag. Show Affiliations »
Abstract
Mesh： See more » Adverse Drug Reaction Reporting Systems/standardsAntineoplastic Agents/administration & dosageAntineoplastic Agents/adverse effectsBone Density Conservation Agents/adverse effectsConsumer BehaviorDiphosphonates/administration & dosageDiphosphonates/adverse effectsDrug ApprovalHumansImidazoles/administration & dosageImidazoles/adverse effectsMultiple Myeloma/drug therapyOsteonecrosis/chemically inducedPamidronateProduct Surveillance, PostmarketingUnited StatesUnited States Food and Drug AdministrationZoledronic Acid
Substances： See more » Antineoplastic AgentsBone Density Conservation AgentsDiphosphonatesImidazolesZoledronic AcidPamidronate
Year: 2005 PMID： 16368939 DOI： 10.1093/jnci/dji458
Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506